Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Validate GMU's Protein Biomarkers

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will work with researchers at George Mason University to validate protein biomarkers GMU discovered using Thermo Fisher’s mass spectrometry technology.
 
Scientists at GMU’s Center for Applied Proteomics and Molecular Medicine (CAPMM) will use Thermo Fisher’s Quantum Ultra triple quadrupole mass spectrometers to discover cancer biomarkers, which the company will cross-validate at its Biomarker Research Initiatives in Mass Spectrometry Center.
 
"We're focused on developing a robust, reproducible protein biomarker analytical workflow that could shave years off the process of translating biomarkers into validated clinical diagnostic laboratory tests," Emanuel Petricoin, who chairs GMU’s Department of Molecular and Microbiology, said in a statement.
 

CAPMM Co-director Lance Liotta called the processes of validating and verifying biomarkers “the chief bottlenecks in the entire research community,” and he said this collaboration could help to “ease, if not possibly eliminate, this challenge all together.”

 

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.